Amisulpride versus other atypical antipsychotics for schizophrenia

Abstract

Background-In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics.

The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

“…Amisulpride and sulpiride are psychotropic drugs in the class of substituted benzamides that are used to treat schizophrenia (36)(37)(38). Both drugs are selective dopamine receptor D2 blockers and need to pass the blood-brain barrier in order to reach their site of action.…”

The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

“…Amisulpride and sulpiride are psychotropic drugs in the class of substituted benzamides that are used to treat schizophrenia (36)(37)(38). Both drugs are selective dopamine receptor D2 blockers and need to pass the blood-brain barrier in order to reach their site of action.…”

Quality of life and functioning in first‐episode psychosisChinese patients with different antipsychotic medications

“…Amisulpride is a selective dopamine D2/3 antagonist which is different from many other second‐generation antipsychotics that have no significant affinity for serotonergic (5HT2A), muscarinic, cholinergic or α‐adrenergic receptors . Previous studies suggested that amisulpride is better in improvement of negative symptoms and it causes fewer extrapyramidal side‐effects, weight gain, and specific endocrinological and sexual disorders than risperidone in patients with psychosis . The selective action at limbic cortical dopamine D2/D3 receptors that cause less severe extrapyramidal side‐effects and 5‐HT7A receptor antagonism underlying antidepressant actions may contribute to the difference in QoL …”

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

“…All manufacturers of SGAs were contacted for further details of published studies and asked for unpublished trials; first authors of included studies were contacted for missing information. Detailed methodology is published in the Cochrane library in systematic reviews of individual SGAs in comparison to other SGAs (Komossa et al, 2007; Komossa et al, 2009a; Komossa et al, 2009c; Komossa et al, 2009b; Komossa et al, 2010c; Komossa et al, 2010a; Komossa et al, 2010d; Komossa et al, 2010b). Here we present a summary to show an overall picture of the metabolic side effects of the SGAs.…”

The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

“…Amisulpride and sulpiride are psychotropic drugs in the class of substituted benzamides that are used to treat schizophrenia (36)(37)(38). Both drugs are selective dopamine receptor D2 blockers and need to pass the blood-brain barrier in order to reach their site of action.…”

Quality of life and functioning in first‐episode psychosisChinese patients with different antipsychotic medications

“…Amisulpride is a selective dopamine D2/3 antagonist which is different from many other second‐generation antipsychotics that have no significant affinity for serotonergic (5HT2A), muscarinic, cholinergic or α‐adrenergic receptors . Previous studies suggested that amisulpride is better in improvement of negative symptoms and it causes fewer extrapyramidal side‐effects, weight gain, and specific endocrinological and sexual disorders than risperidone in patients with psychosis . The selective action at limbic cortical dopamine D2/D3 receptors that cause less severe extrapyramidal side‐effects and 5‐HT7A receptor antagonism underlying antidepressant actions may contribute to the difference in QoL …”

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

“…All manufacturers of SGAs were contacted for further details of published studies and asked for unpublished trials; first authors of included studies were contacted for missing information. Detailed methodology is published in the Cochrane library in systematic reviews of individual SGAs in comparison to other SGAs (Komossa et al, 2007; Komossa et al, 2009a; Komossa et al, 2009c; Komossa et al, 2009b; Komossa et al, 2010c; Komossa et al, 2010a; Komossa et al, 2010d; Komossa et al, 2010b). Here we present a summary to show an overall picture of the metabolic side effects of the SGAs.…”

The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family

“…Amisulpride and sulpiride are psychotropic drugs in the class of substituted benzamides that are used to treat schizophrenia (36)(37)(38). Both drugs are selective dopamine receptor D2 blockers and need to pass the blood-brain barrier in order to reach their site of action.…”

Quality of life and functioning in first‐episode psychosisChinese patients with different antipsychotic medications

“…Amisulpride is a selective dopamine D2/3 antagonist which is different from many other second‐generation antipsychotics that have no significant affinity for serotonergic (5HT2A), muscarinic, cholinergic or α‐adrenergic receptors . Previous studies suggested that amisulpride is better in improvement of negative symptoms and it causes fewer extrapyramidal side‐effects, weight gain, and specific endocrinological and sexual disorders than risperidone in patients with psychosis . The selective action at limbic cortical dopamine D2/D3 receptors that cause less severe extrapyramidal side‐effects and 5‐HT7A receptor antagonism underlying antidepressant actions may contribute to the difference in QoL …”

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

“…All manufacturers of SGAs were contacted for further details of published studies and asked for unpublished trials; first authors of included studies were contacted for missing information. Detailed methodology is published in the Cochrane library in systematic reviews of individual SGAs in comparison to other SGAs (Komossa et al, 2007; Komossa et al, 2009a; Komossa et al, 2009c; Komossa et al, 2009b; Komossa et al, 2010c; Komossa et al, 2010a; Komossa et al, 2010d; Komossa et al, 2010b). Here we present a summary to show an overall picture of the metabolic side effects of the SGAs.…”